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Hypertension is a global health issue causing almost 10 million deaths annually, with a 
disproportionate number occurring in low- and middle-income countries. The condition can 
be managed effectively, but there is a need for innovation in healthcare delivery to alleviate 
its burden. This paper presents a number of innovative delivery models from a number 
of different countries, including Kenya, Ghana, Barbados and India. These models were 
presented at the London Dialogue event, which was cohosted by the Novartis Foundation 
and the London School of Hygiene & Tropical Medicine Centre for Global Noncommunicable 
Diseases on 1 December 2015. It is argued that these models are applicable not only to 
hypertension, but provide valuable lessons to address other noncommunicable diseases.
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High blood pressure (BP) is the world’s leading disease burden, responsible for almost 10 million 
deaths annually, which is equal to the number of deaths caused by all infectious diseases com-
bined [1,2]. The majority of this mortality occurs in low- and middle-income countries (LMIC)s, 
where people are presenting with hypertension at a younger age [3] and experience worse outcomes 
than in high-income countries [4]. Moreover, the proportion of people with undiagnosed, untreated 
or uncontrolled hypertension is significantly higher in LMICs, mainly due to limited awareness 
and overburdened health systems [3].
Changing lifestyles (increased intake of processed food, alcohol and tobacco consumption, limited 
physical activity), rapid urbanization, aging populations and genetic factors all play a role in the 
increasing hypertension epidemic in LMICs [3,5–6]. There are other underlying factors that are not 
completely understood, including increasing prevalence of low birth weights or repeated episodes 
of certain infectious diseases [7,8].
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Addressing the needs of patients with chronic 
diseases is challenging for health systems already 
overwhelmed by infectious diseases and mater-
nal-and-child health issues. There is an urgent 
need for innovation in healthcare delivery to 
tackle this dual burden. A recent study has 
shown it is possible to substantially improve 
hypertension control at a national level in only 
a few years [9]. Moreover, innovative care models 
for hypertension that successfully decrease the 
workload in health systems and improve patient 
outcomes could also create solutions for handling 
other noncommunicable diseases (NCD)s. This 
was the topic of the recent London Dialogue, 
cohosted by the Novartis Foundation and the 
London School of Hygiene & Tropical Medicine 
Centre for Global NCDs on 1 December 2015.
Innovative delivery models for hyperten-
sion were presented from Kenya, Ghana, 
Barbados and India. The Sustainable model for 
Cardiovascular health by Adjusting Lifestyle and 
treatment with Economic perspective in settings 
of Urban Poverty (SCALE-UP) program in the 
urban slums of Nairobi, Kenya, demonstrated 
the importance of designing programs around 
patients’ daily reality. An excellent set of inter-
ventions addressed gaps in the hypertension 
delivery chain (improving awareness, access to 
screening and quality treatment and promoting 
adherence). As part of the program, 50 commu-
nity health workers were trained and equipped 
to conduct door-to-door hypertension screening, 
seven patient support groups were formed, six 
clinical officers and nurses were trained and a 
standardized clinical treatment guideline was 
developed. However, despite these interventions, 
the program demonstrated limited success; while 
three in four hypertensive patients were treated 
at least once, only one in three participants was 
retained in treatment for >6 months and BP con-
trol was achieved by just 6% of patients [10]. It 
highlighted that job-seeking takes priority over 
healthcare-seeking behavior in these settings. 
Alongside financial reasons, patients failed to 
adhere to treatment, mainly because of limited 
opportunities to attend health services during 
the day.
The Ghana Community Hypertension 
Improvement Project (ComHIP) has the patient 
at the center of intervention, using digital health 
to empower individuals in their own disease 
management, for example, through adherence 
support and lifestyle education. This model 
maximizes screening and care delivery outside 
the health system, by shifting these tasks to 
local pharmacies and community nurses, all 
connected by digital health to facilitate coor-
dinated patient care. The model is based on a 
successful model in HIV, demonstrating how 
learnings from infectious diseases can be applied 
to NCDs.
India also provides innovative models for 
hypertension including the use of front-line 
healthcare workers to initiate structured behav-
ior change (reduction of salt, harmful intake of 
alcohol, fruit and vegetable intake). One further 
example used innovative software to aid evalu-
ation, risk stratification, drug management and 
lifestyle interventions for hypertension patients, 
and was associated with reductions in BP [11]. 
In Barbados, an overall lack of standardization 
in hypertension management (including poor 
adherence to hypertension protocols) was identi-
fied as a barrier to achieving successful hyper-
tension control. The introduction and positive 
impact of new hypertension treatment guidelines 
showed that greater standardization to improve 
care is essential. Key to the success of this initia-
tive was early identification and involvement of 
stakeholder groups.
However, healthcare alone is not sufficient to 
fully address hypertension, because many of the 
underlying factors fall beyond the scope of health 
systems. Tackling socioeconomic determinants 
could have much more impact and demands less 
effort from individuals [3]. There is consequently 
a need for a comprehensive approach to tackling 
hypertension in LMICs, based on cross-sectoral 
collaboration to bring together expertise and 
resources from private and public sectors.
Focusing on nontraditional health aspects 
has proven successful in high-income settings. 
One approach is the ‘age-friendly city’ example 
of New York, where older persons are asked to 
identify necessary changes across domains, such 
as transportation, housing, social participation, 
employment and health to improve their lives. 
This information is then used to shape actions by 
government agencies and private sector organiza-
tions. These principles are valid for LMICs as 
demonstrated by the WHO, highlighting the 
success, scalability and affordability of other 
population-based measures [12].
The hypertension challenge in the major-
ity world has unprecedented scope. As the 
World Heart Federation’s Roadmap dem-
onstrates, proven cost-effective lifestyle and 
medical interventions to prevent and manage 
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hypertension exist, though uptake is still unac-
ceptably low and is reflected in important care 
gaps in LMICs [13]. Hypertension is one of 
the easiest NCDs to diagnose and treat, but 
there is a pressing need for new ideas and evi-
dence to support the effectiveness of innovative 
models that are affordable, culturally accept-
able and sustainable at scale. Future models 
must be designed around a thorough analysis 
of patients’ reality. Optimizing the use of digi-
tal health to transform service delivery, reduce 
costs, broaden access and maximize outside 
screening and care opportunities could help 
alleviate the burden of NCDs on health sys-
tems. Innovative care models linked to changes 
in community conditions could address wider 
social determinants. However, this requires a 
holistic approach involving a variety of part-
ners. If successful, treatment coverage of the 
condition is one of the candidate indicators to 
monitor universal health coverage and lessons 
from hypertension may prove applicable to 
innovative healthcare delivery models for other 
NCDs that are more difficult to diagnose and 
treat.
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